Skip to main content
OpenTrials

Clinical trial condition

Neuroectodermal Tumors, Primitive, Peripheral

Explore clinical trials studying Neuroectodermal Tumors, Primitive, Peripheral. Study availability and eligibility vary by location and protocol.

504 public trials 95 recruiting studies
Refine in advanced search Browse all conditions

Neuroectodermal Tumors, Primitive, Peripheral trial results

Recruiting

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

NCT06541262

Conditions
Ewing Sarcoma, Liposarcoma, Myosarcoma, +19 more
Locations
  • University of Alabama/Children's of Alabama Birmingham, Alabama, United States
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • UCSF Benioff Children's Hospital Oakland Oakland, California, United States
  • Rady Children's Hospital San Diego, California, United States
View all 23 locations
View Trial Details
Recruiting

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

NCT06540963

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +7 more
Locations
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Connecticut Children's Hospital Hartford, Connecticut, United States
  • Nicklaus Children's Hospital Miami, Florida, United States
  • Arnold Palmer Hospital for Children Orlando, Florida, United States
View Trial Details
Recruiting

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

NCT06465199

Conditions
Atypical Teratoid/Rhabdoid Tumor, Brain Diseases, Brain Neoplasms, +30 more
Locations
  • University of Alabama/Children's of Alabama Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Connecticut Children's Hospital Hartford, Connecticut, United States
  • Nicklaus Children's Hospital Miami, Florida, United States
View all 14 locations
View Trial Details
Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119

Conditions
Adenocarcinoma, Adnexal Diseases, Carcinoma, +90 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital of Orange County Orange, California, United States
  • Lucile Packard Children's Hospital Stanford University Palo Alto, California, United States
View all 21 locations
View Trial Details
Recruiting

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916

Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neoplasms, +9 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Phoenix Childrens Hospital Phoenix, Arizona, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente Downey Medical Center Downey, California, United States
View all 164 locations
View Trial Details
Recruiting

APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

NCT05701306

Conditions
Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, +8 more
Locations
  • Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
  • Tongji Hospital, Huazhong University of Science and Technology (HUST) Wuhan, Hubei, China
  • Tianjin Medical University Cancer Institute & Hospital Tianjin, Tianjin Municipality, China
View Trial Details

Related conditions